OSE Immunotherapeutics SA: OSE Immunotherapeutics to Continue the Clinical Development in Ulcerative Colitis with Full Rights to Lusvertikimab
First-in-class Lusvertikimab (OSE-127) is the most advanced anti-IL-7R mAb. Ongoing clinical Phase 2 trial in Ulcerative Colitis sponsored by OSE Immunotherapeutics after positive futility
United States France General Nicolas Poirier Thomas Guillot Florence Portejoie Nantes University Hospital
Source: finanznachrichten.de